PRESS RELEASE published on 06/12/2025 at 22:42, 1 year 2 months ago Inside Information / Other news releases GeNeuro SA's French subsidiary GeNeuro Innovation SAS enters receivership proceedings amidst parent company's debt-restructuring efforts Autoimmune Diseases GeNeuro SA Neurodegenerative Diseases Debt-restructuring Receivership Proceedings
PRESS RELEASE published on 06/12/2025 at 22:42, 1 year 2 months ago Informations privilégiées / Autres communiqués GeNeuro annonce l’ouverture de la procédure de redressement judiciaire de sa filiale GeNeuro Innovation SAS. La société cherche à se restructurer pour surmonter ses difficultés financières Restructuration Difficultés Financières Redressement Judiciaire GeNeuro Sursis Concordataire
BRIEF published on 12/13/2024 at 12:02, 1 year 8 months ago Citigroup reduces its stake in GENEURO SA Euronext Paris Sale Of Shares Threshold Crossing GeNeuro SA Citigroup
BRIEF published on 12/13/2024 at 12:02, 1 year 8 months ago Citigroup réduit sa participation dans GENEURO SA Euronext Paris Franchissement De Seuil Vente D'actions GeNeuro SA Citigroup
PRESS RELEASE published on 12/13/2024 at 11:57, 1 year 8 months ago Franchissement de seuils Déclaration de franchissement de seuils de Citigroup Global Markets Limited concernant GENEURO SA publiée le 12 décembre 2024 Déclaration Franchissement De Seuils GeNeuro SA Citigroup Global Markets Limited
BRIEF published on 12/06/2024 at 18:35, 1 year 9 months ago GeNeuro dévoile son nouveau médicament de précision pour la SLA Médecine De Précision GeNeuro Traitement De La SLA GNK-301 ENVIRONNEMENT HERV-K
BRIEF published on 12/06/2024 at 18:35, 1 year 9 months ago GeNeuro's New Precision Medicine for ALS Unveiled Precision Medicine GeNeuro ALS Treatment GNK-301 HERV-K ENV
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 9 months ago Informations privilégiées / Autres communiqués Nouvelle approche de médecine de précision pour la SLA avec GNK-301 de GeNeuro présentée au 35e Symposium international sur la SLA/MMN Recherche Médecine De Précision GeNeuro SLA GNK-301
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 9 months ago Inside Information / Other news releases GeNeuro presents groundbreaking findings on precision medicine for ALS patients with GNK-301 at the 35th International Symposium on ALS/MND. Research highlights potential of targeting HERV-K ENV to transform ALS treatment Precision Medicine ALS GeNeuro GNK-301 HERV-K ENV
BRIEF published on 11/06/2024 at 09:48, 1 year 10 months ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
Published on 09/12/2026 at 02:35, 11 hours 18 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 53 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 48 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 28 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 53 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 23 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 38 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 43 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 8 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 38 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
